TAILIEUCHUNG - HIGHLIGHTS OF PRESCRIBING INFORMATION

In empirical studies of retirement decisions of the elderly, health is often found to have a large, if not dominant, effect. Depending on which health measures are used, these estimated effects may be biased estimates of the causal effect of health on the dependent variable(s).Research indicates that subjective, self-assessed health measures may be affected by endogenous reporting behaviour and even if an objective health measure is used, it is not likely . | HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LATUDA safely and effectively. See full prescribing information for LATUDA. LATUDA lurasidone hydrochloride tablets for oral use Initial . Approval 2010 WARNING INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for the treatment of patients with dementia-related psychosis . -------------------------RECENT MAJOR CHANGES------------------------------- Dosage and Administration Schizophrenia 04 2012 Dosage and Administration Dose Modifications in Special Populations 04 2012 -------------------------INDICATIONS AND USAGE------------------------------ LATUDA is an atypical antipsychotic indicated for the treatment of patients with schizophrenia 1 . Efficacy was established in five 6-week controlled studies of adult patients with schizophrenia . ----------------------DOSAGE AND ADMINISTRATION----------------------------- The recommended starting dose of LATUDA is 40 mg once daily . The maximum recommended dose is 160 mg once daily . LATUDA should be taken with food . Moderate and severe renal impairment Recommended starting dose is 20 mg and the maximum recommended dose is 80 mg . Moderate and severe hepatic impairment Recommended starting dose is 20 mg. The maximum recommended dose is 80 mg in moderate hepatic impairment and 40 mg in severe hepatic impairment . Concomitant use with a moderate CYP3A4 inhibitor . diltiazem Recommended starting dose is 20 mg and the maximum recommended dose is 80 mg ----------------------DOSAGE FORMS AND STRENGTHS---------------------------- Tablets 20 mg 40 mg 80 mg and 120 mg 3 ----------------------------CONTRAINDICATIONS------------------------------- Known .

• Sức khỏe người cao tuổi
• sales restrictions
• between heterogeneity
• Allergen Bioinformatics
• Recent Trends
• Developments
• Family Based Studies
• versus non Internet
• Manufacturing
• Mechanical Improvement
• Ramie Woven
• Reinforced Starch
• Pricing Functional
• Optimal Portfolios
• Equilibrium Pricing
• Diagrammatic Representation
• Contingent Claims